Certara, Inc. will release its financial results for the second quarter of 2026 before market open on August 4, 2026. The company, a global leader in model-informed drug development, scheduled a conference call at 8:30AM ET to discuss the quarterly performance. This announcement provides investors with a timeline to assess the company's financial health and operational progress during the period.

Investors interested in participating in the conference call are required to register online at least one day in advance. The company has emphasized early registration to ensure access to the live discussion. A live and archived webcast of the event will also be available on the "Investors" section of the Certara website at https://ir.certara.com/ .

Certara specializes in transforming drug discovery and development by helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions integrate biosimulation, clinical intelligence, and regulatory science into the workflows of drug developers worldwide. The company serves a diverse client base, including more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies.

The upcoming earnings release will provide detailed insights into Certara's revenue, profitability, and strategic initiatives for Q2 2026. Stakeholders can access the financial results and the accompanying webcast to evaluate the company's performance against market expectations.

Pomerantz LLP is investigating claims on behalf of investors of Certara concerning potential securities fraud or other unlawful business practices by the company and its officers. The investigation follows significant stock declines triggered by disappointing financial results and high-level executive departures. Investors are advised to contact the firm regarding the class action proceedings.

On May 11, 2026, Certara reported its first quarter 2026 financial results, revealing a decline in key operational metrics. Services revenue fell 4% year-over-year to $57.2 million, while services bookings dropped 14% year-over-year to $66.6 million. The company attributed the softer performance to Tier 1 customers in Model-Informed Drug Development (MIDD) services and described the overall services performance as "mixed." Additionally, Certara announced its exit from the regulatory business within its service segment.

In response to these disclosures, Certara’s stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026. The company further noted inconsistency between software and services performance over recent quarters during the discussion of its results.

Subsequently, on June 17, 2026, Certara announced that John Gallagher, the Company’s Chief Financial Officer, would resign effective July 14, 2026. Following this news, the stock price declined $0.49 per share, or 8.13%, to close at $5.54 per share on June 18, 2026.

Key Financial and Corporate Events